#3 - Senseonics (NYSE:SENS)
Senseonics Holdings, Inc. (NYSEAMERICAN: SENS) makes this list because of the way the company is disrupting the diabetes industry with its Eversense implantable continuous glucose management device (CMD) that can be connected to a user’s smartphone via a mobile app.
One of the obstacles to the mass adoption of the Eversense system is, of course, cost. The system was not covered by many insurers. On that front, however, Senseonics got a lift when UnitedHealth Group Incorporated (NYSE: UNH) recently announced that it will provide coverage for the Eversense system. Starting July 1, 2023, the company will cover patients with type-1 and insulin-requiring type 2 diabetes. According to Senseonics president and chief executive officer (CEO), Tim Goodnow, this will allow nearly all insured adults in the United States to have access to the system.
SENS stock was part of the meme stock movement and has taken investors on a wild ride in the last two years. The stock has closed with a price of $4.63 in February 2021. But the stock is trading at just 75 cents per share as of this writing.
About Senseonics
Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.
More- Current Price
- $0.93
- Consensus Rating
- Buy
- Ratings Breakdown
- 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $2.00 (114.1% Upside)
